Intermediate OLGA / OLGIM Stages as Early Risk Markers for Gastric Cancer: A Systematic Review and Meta‐Analysis
Authors:
- Juan Sebastián Frías‐OrdóñezJFJuan Sebastián Frías‐Ordóñez
- Sebastián Niño‐RamírezSNSebastián Niño‐Ramírez
- José Darío Portillo‐MiñoJPJosé Darío Portillo‐Miño
- Arnoldo Riquelme PérezAPArnoldo Riquelme Pérez
- Lina Otero‐ParraLOLina Otero‐Parra
- Hernando Marulanda‐FernándezHMHernando Marulanda‐Fernández
- Elder Otero‐RamosEOElder Otero‐Ramos
- William Otero‐ReginoWOWilliam Otero‐Regino
- 1 September 2026
- journal article
- review article
- Published by Wiley in Helicobacter
- Vol. 31 (5) , e70168
Abstract
Background: The Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) systems stratify gastric cancer (GC) risk according to the extent of gastric atrophy and intestinal metaplasia. However, the clinical significance of intermediate stages remains uncertain. Objective: To evaluate the association between OLGA/OLGIM stages and GC, with particular focus on the potential role of intermediate stages as early histological risk markers. Methods: A systematic review and meta‐analysis (PROSPERO CRD42024549931) was conducted according to PRISMA 2020 guidelines. Cohort, case–control, and cross‐sectional studies reporting GC incidence or prevalence according to OLGA and/or OLGIM stage were included. Methodological quality was assessed using the Newcastle‐Ottawa Scale and certainty of evidence using GRADE. Random‐effects models were used to calculate pooled odds ratios (OR) and risk ratios (RR). Results: Twenty‐eight studies involving 23,390 patients were included. Methodological quality was high and certainty of evidence was moderate. Advanced OLGA III–IV and OLGIM III–IV stages were strongly associated with GC (OR 6.49 and 7.76; RR 13.26 and 4.34, respectively). Intermediate stages were also associated with GC in observational studies: OLGA II (OR 2.77; 95% CI 1.83–4.20; I 2 = 71%) and OLGIM II (OR 3.63; 95% CI 2.90–4.55; I 2 = 0%). However, prospective cohort studies did not demonstrate a statistically significant increase in future GC incidence for OLGA II (RR 1.20; 95% CI 0.85–1.69). Conclusions: Intermediate OLGA and OLGIM stages may represent early histological markers associated with gastric carcinogenesis. Prospective studies are required to determine their predictive value and potential implications for surveillance strategies, particularly in high‐incidence populations.Keywords
This publication has 41 references indexed in Scilit:
- Chilean Association of Digestive Endoscopy (ACHED) guidelines for the detection of early gastric cancer and surveillance of gastric premalignant conditions in high-risk populationsGastroenterología y Hepatología, 2025
- Standardizing endoscopic protocols increases detection of gastric cancer during surveillance of patients with precancerous conditions: a systematic review and meta-analysisDigestive and Liver Disease, 2025
- 40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer preventionThe Lancet, 2024
- Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up studyGastric Cancer, 2023
- AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert ReviewGastroenterology, 2021
- Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low-risk regionDigestive and Liver Disease, 2021
- The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous LesionsGastroenterology, 2021
- The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysisGastric Cancer, 2018
- The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritisGastrointestinal Endoscopy, 2010
- Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990sEuropean Journal of Cancer, 2008